NANOVIRICIDES, INC. (49) | Business Finance (32)
Browse by Subcategory
Recent Contracts
-
Underwriting Agreement with Kingswood Capital Markets, a Division of Benchmark Investments, Inc. dated July 8, 2020
(Filed With SEC on July 13, 2020)
-
Placement Agent Agreement, dated May 21, 2020 by and between among NanoViricides, Inc. Maxim Group LLC and Kingswood Capital Markets, a division of Benchmark Investments, Inc
(Filed With SEC on May 22, 2020)
-
Form of Securities Purchase Agreement dated May 21, 2020 by and between NanoViricides, Inc. and certain purchasers
(Filed With SEC on May 22, 2020)
-
Form of Common Stock Purchase Agreement
(Filed With SEC on January 28, 2020)
-
Form of Exchange Agreement
(Filed With SEC on January 28, 2020)
-
Form of Series A Conversion Waiver
(Filed With SEC on January 8, 2020)
-
Open End Mortgage Note
(Filed With SEC on December 19, 2019)
-
Form of Representatives Warrant
(Filed With SEC on September 27, 2019)
-
Underwriting with Aegis Capital Corp. dated January 21, 2020
(Filed With SEC on January 27, 2020)
-
Certificate of Amendment to Certificate of Designation of Series A Convertible Preferred Stock
(Filed With SEC on January 8, 2020)
-
Certificate of Amendment to Certificate of Designation of Series A Convertible Preferred Stock
(Filed With SEC on January 8, 2020)
-
Form of Series A Conversion Waiver
(Filed With SEC on January 7, 2020)
-
Certificate of Amendment to Certificate of Designation of Series A Convertible Preferred Stock
(Filed With SEC on January 7, 2020)
-
Certificate of Amendment to Certificate of Designation of Series A Convertible Preferred Stock
(Filed With SEC on January 7, 2020)
-
Certificate of Amendment to Certificate of Designation of Series A Convertible Preferred Stock
(Filed With SEC on December 23, 2019)
-
Form of Series A Conversion Waiver
(Filed With SEC on December 23, 2019)
-
Certificate of Amendment to Certificate of Designation of Series A Convertible Preferred Stock
(Filed With SEC on December 23, 2019)
-
Deferred Expense Exchange Agreement
(Filed With SEC on December 19, 2019)
-
Certificate of Amendment to Certificate of Designation of Series A Convertible Preferred Stock
(Filed With SEC on December 17, 2019)
-
Certificate of Amendment to Certificate of Designation of Series A Convertible Preferred Stock
(Filed With SEC on December 17, 2019)
-
Form of Series A Conversion Waiver
(Filed With SEC on December 17, 2019)
-
Certificate of Amendment to Certificate of Designation of Series A Convertible Preferred Stock
(Filed With SEC on November 29, 2019)
-
Certificate of Amendment to Certificate of Designation of Series A Convertible Preferred Stock
(Filed With SEC on November 29, 2019)
-
Form of Series A Conversion Waiver
(Filed With SEC on November 29, 2019)
-
Form of Series A Conversion Waiver
(Filed With SEC on September 27, 2019)
-
Form of Common Stock Purchase Warrant
(Filed With SEC on September 27, 2019)
-
Form of Pre-Funded Warrant
(Filed With SEC on September 27, 2019)
-
Certificate of Amendment to Certificate of Designation of Series A Convertible Preferred Stock
(Filed With SEC on September 27, 2019)
-
Certificate of Amendment to Certificate of Designation of Series A Convertible Preferred Stock
(Filed With SEC on September 27, 2019)
-
Form of Underwriting Agreement
(Filed With SEC on September 27, 2019)
-
Form of Common Stock Purchase Warrant
(Filed With SEC on March 1, 2019)
-
Form of Securities Purchase Agreement dated February 27, 2019 by and between NanoViricides, Inc. and certain purchasers
(Filed With SEC on March 1, 2019)